<DOC>
	<DOCNO>NCT01171976</DOCNO>
	<brief_summary>The purpose study demonstrate two investigational treatment regimens potential result superior visual acuity improvement compare ranibizumab pro nata ( PRN=as need ) treatment regimen .</brief_summary>
	<brief_title>Efficacy Safety Ranibizumab Two `` Treat Extend '' Treatment Algorithms Versus Ranibizumab As Needed Patients With Macular Edema Visual Impairment Secondary Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Vision Disorders</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Patient Patients Type 1 Type 2 diabetes mellitus ( accord American Diabetes Association World Health Organization [ WHO ] guideline ) glycosylated hemoglobin ( HbA1c ) ≤ 12.0 % screening ( Visit 1 ) . Patients diet , exercise , and/or pharmacological treatment diabetes . Treatment diabetes must stable least 3 month . Ocular Patients visual impairment due DME least one eye eligible laser treatment opinion investigator . If eye eligible , one bad visual acuity , assess Visit 1 , select investigator study eye . BCVA ≥ 39 ≤78 letter study eye , inclusively , use Early Treatment Diabetic Retinopathy Study ( ETDRS ) like visual acuity test chart test distance 4 meter ( approximate Snellen equivalent 20/32 20/160 ) screening . Concomitant condition study eye permit , opinion investigator , prevent improvement visual acuity study treatment . Patient Compliance/ Administrative Pregnant nursing ( lactate ) woman . Ocular medical history Active intraocular inflammation ( grade trace ) either eye enrollment . Any active infection ( e.g . conjunctivitis , keratitis , scleritis , uveitis , endophthalmitis ) either eye time enrollment . History uveitis either eye time . Structural damage within 0.5 disc diameter center macular study eye likely preclude improvement visual acuity follow resolution macular edema . Uncontrolled glaucoma either eye screening . Prior Ocular treatment Panretinal laser photocoagulation study eye within 6 month prior randomization . Focal/grid laser photocoagulation study eye within 3 month prior randomization . Treatment antiangiogenic drug either eye . Systemic condition treatment History stroke within 6 month prior enrollment . Renal failure require dialysis . Untreated diabetes mellitus . Blood pressure systolic &gt; 160 mmHg diastolic &gt; 100 mmHg . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>DME</keyword>
	<keyword>Diabetic macula edema</keyword>
	<keyword>RETAIN</keyword>
	<keyword>ranibizumab</keyword>
</DOC>